Nutra Pharma

Nutra Pharma PEG

PEG Ratio (Price/Earnings-to-Growth) of Nutra Pharma (NPHC) as of Nov 4, 2026.

PEG

-

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Nutra Pharma is 2026 - . PEG Ratio (Price/Earnings-to-Growth) of Nutra Pharma was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nutra Pharma Stock analysis

What does Nutra Pharma do? Nutra Pharma is an American biotechnology company specializing in researching, developing, and marketing medications for the treatment of neurological, autoimmune, and cancer diseases. The company was founded in 2000 and is headquartered in Coral Springs, Florida. Nutra Pharma initially focused on developing dietary supplements for joint pain and inflammation relief. However, in 2004, the company made a significant breakthrough with the introduction of Nyloxin, a natural pain reliever made from a unique combination of toxins from marine animals such as bees, snakes, and spiders. Nyloxin aims to provide a safe and effective alternative to conventional pain medications like ibuprofen and opioids. In addition to Nyloxin, Nutra Pharma also offers several other products including Sinus Buster, a nasal spray designed to alleviate headaches and migraines, and Pet Pain, a veterinary pain medication for pets. The company is also involved in the research and development of therapeutics for autoimmune diseases like multiple sclerosis and HIV. Nutra Pharma holds patents for its novel drugs and drug candidates, including its ReceptoPharm platform technology currently being utilized in Alzheimer's disease drug development. The company has built a wide network of distribution partners to market its products in the United States and other countries. It also employs an aggressive marketing strategy to raise awareness among physicians, pharmacists, veterinarians, and end consumers. Additionally, Nutra Pharma supports nonprofit organizations dedicated to researching and developing therapeutics for rare and incurable diseases. Overall, Nutra Pharma has become a significant player in the biotechnology industry, developing innovative products and technologies for pain, inflammation, and various diseases. The company has established itself as a valuable partner to distribution partners and nonprofit organizations, benefiting from its expertise and products. Nutra Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nutra Pharma stock

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Nutra Pharma since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Nutra Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Nutra Pharma

All Key Metrics — Nutra Pharma